±¹³»µµ¼
Àü°øµµ¼/´ëÇб³Àç
ÀǾàÇа£È£°è¿
2013³â 9¿ù 9ÀÏ ÀÌÈÄ ´©Àû¼öÄ¡ÀÔ´Ï´Ù.
Á¤°¡ |
300,000¿ø |
---|
270,000¿ø (10%ÇÒÀÎ)
15,000P (5%Àû¸³)
ÇÒÀÎÇýÅÃ | |
---|---|
Àû¸³ÇýÅà |
|
|
|
Ãß°¡ÇýÅÃ |
|
À̺¥Æ®/±âȹÀü
¿¬°üµµ¼
»óÇ°±Ç
ÀÌ»óÇ°ÀÇ ºÐ·ù
Ã¥¼Ò°³
¢º ÀÌ Ã¥Àº Â÷¼¼´ë ¹ÙÀÌ¿À»ê¾÷ÀÇ ÇÙ½É ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±â¼úµ¿ÇâÀ» ´Ù·é À̷мÀÔ´Ï´Ù. Â÷¼¼´ë ¹ÙÀÌ¿À»ê¾÷ÀÇ ÇÙ½É ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±â¼úµ¿ÇâÀÇ ±âÃÊÀûÀÌ°í Àü¹ÝÀûÀÎ ³»¿ëÀ» ÇнÀÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Â÷¼¼´ë ¹ÙÀÌ¿À»ê¾÷ÀÇ ÇÙ½É ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±â¼úµ¿Çâ
Á¦1Àå ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È(Microbiome) °³¿ä ¹× NGS À¯Àüü ºÐ¼®
1. ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È(Microbiome) °³¿ä
1-1. ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È(Microbiome) µîÀå¹è°æ ¹× °³¿ä
1-1-1. ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È(Microbiome) µîÀå ¹è°æ
1-1-2. ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È(Microbiome) °³¿ä ¹× ¿ªÇÒ
(1) ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È(Microbiome) °³¿ä
(2) ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È(Microbiome)ÀÇ ¿ªÇÒ
°¡. ¿µ¾çºÐ Èí¼ö
³ª. ¾à¹°´ë»ç Á¶Àý
´Ù. ¸é¿ªÃ¼°è Á¶Àý
¶ó. °¨¿°¼º Áúȯ ¿¹¹æ
(3) ¹Ì»ý¹°°ú °Ç° ¹× Áúº´°úÀÇ °ü°è
°¡. Àå³»¹Ì»ý¹°
°¡-1. Àå³»¹Ì»ý¹° °³¿ä
°¡-2. Àå³»¹Ì»ý¹° »ýÅ°è
³ª. Àå³»¹Ì»ý¹°°ú Áúº´°úÀÇ °ü°è
³ª-1. Áß°£±Õ(±âȸ±Õ)
³ª-2. À¯ÀͱÕ
³ª-3. À¯ÇرÕ
´Ù. ÈÞ¸Õ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È(Human Microbiome)
´Ù-1. ÇÁ·Î¹ÙÀÌ¿Àƽ½º(probiotics)
´Ù-2. ±¸°À¯»ê±Õ
´Ù-3. ´ëº¯ ¹Ì»ý¹° À̽ļú(Fecal Microbiota Transplantation, ºÐº¯ À̽Ä)
¨ç ´ëº¯ ¹Ì»ý¹° À̽Ä((FMT)ÀÇ °³³ä
¨è ´ëº¯ ¹Ì»ý¹° À̽Ä((FMT) °úÁ¤
¨é ´ëº¯ ¹Ì»ý¹° À̽Ä((FMT)ÀÇ ¾ÈÀü¼º
2. NGS À¯Àüü ºÐ¼® ±â¼ú
2-1. À¯ÀüüÇÐ
2-1-1. À¯Àüü ºÐ¼® °³¿ä
(1) À¯Àüü °³³ä
(2) À¯ÀüÀÚ º¯ÀÌ(genetic variation)
(3) À¯ÀüÁ¤º¸ ºÐ¼®ÀÇ Á¾·ù
°¡. ÀüÀå À¯Àüü ºÐ¼®(Whole Genome Sequencing, WGS)
³ª. ÀüÀå ¿¢¼Ø ºÐ¼®(Whole Exome Sequencing, WES)
´Ù. À¯ÀüÀÚ ÆгΠºÐ¼®(Gene Panel)
¶ó. ´ÜÀÏ¿°±â´ÙÇü¼º ºÐ¼®(Single Nucleotide Polymorphism, SNP)
2-1-2. À¯Àüü Á¤º¸ºÐ¼®
(1) ´ÜÀÏ À¯ÀüÀÚ °Ë»ç(Sanger sequencing¡¤»ý¾î½ÃÄö½Ì)
(2) ÈÞ¸Õ°Ô³ðÇÁ·ÎÁ§Æ®(Human Genome Project)
(3) Â÷¼¼´ë ¿°±â¼¿ ºÐ¼®(Next Generation Sequencing)
2-2. Â÷¼¼´ë ¿°±â¼¿ ºÐ¼®(NGS) ±â¼ú
2-2-1. Â÷¼¼´ë ¿°±â¼¿ ºÐ¼®(NGS) ±â¼ú °³¿ä
2-2-2. NGS Àå³»±ÕÃÑ ºÐ¼®(Gut Microbiota Analysis, GMA)
2-3. À¯Àüü °³ÀθÂÃãºÐ¼®
2-3-1. °³ÀÎ À¯ÀüÁ¤º¸ ºÐ¼®
2-3-2. À¯Àüü ±â´É ºÐ¼®(functional genomics)
2-4. Á¤¹ÐÀÇ·á(Precision Medicine)
2-4-1. Á¤¹ÐÀÇ·áÀÇ °³³ä
2-4-2. Á¤¹ÐÀÇ·á(Precision Medicine)ÀÇ ºÐ¾ß
Á¦2Àå ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È(Microbiome) ±â¼úµ¿Çâ
1. ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ¿¬±¸ ºÐ¾ß
1-1. ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ¿¬±¸ °³¹ß µ¿Çâ
1-1-1. 16S rRNA(16S ribosomal RNA) ¾ÚÇø®ÄÜ ½ÃÄö½Ì
1-1-2. ¸ÞŸ°Ô³ð ¼¦°Ç ½ÃÄö½Ì(shotgun sequencing)
1-1-3. ´Ü¼¼Æ÷ ºÐ¼®(Single Cell Analysis, SCA)
1-1-4. ¸ÞŸ Àü»çüÇÐ(Metatranscriptomics)
1-1-5. ¸ÞŸ ÇÁ·ÎÅ׿À¹Í½º(´Ü¹éÁúüÇÐ, proteomics)
1-1-6. ¸ÞŸºí·Î¹Í½º(metabolomics, ´ë»çüÇÐ)
1-1-7. ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿(bio-marker)
1-2. ÈÞ¸Õ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ¿¬±¸°³¹ß µ¿Çâ
1-2-1. Àå³»¹Ì»ý¹°°ú ¾ÆÅäÇǼº ÇǺο°(Atopicdermatitis)
1-2-2. Àå³»¹Ì»ý¹°°ú ÀÚÆóÁõ(autism)
1-2-3. Àå³»¹Ì»ý¹°°ú Á׻󵿸ưæÈÁõ
1-2-4. Àå³»¹Ì»ý¹°°ú ¾Ï(cancer)
1-2-5. Àå³»¹Ì»ý¹°°ú ¾ËÃ÷ÇÏÀÌ¸Ó¿Í ÆÄŲ½¼ Áúȯ(Alzheimer & Parkinson¡¯s disease)
1-2-6. Àå³»¹Ì»ý¹°°ú Ŭ·Î½ºÆ®¸®µð¿ò µðÇÇ½Ç °¨¿°¼º Àå¿°(Clostridium Difficile Infection, C. difficile, CDI)
1-2-7. Àå³»¹Ì»ý¹°°ú Á¶Çöº´(Schizophrenia)
1-2-8. Àå³»¹Ì»ý¹°°ú ºÒ¾ÈÀå¾Ö, ¿ì¿ïÁõ(Depression)
1-2-9. Àå³»¹Ì»ý¹°°ú ´Ù¹ß¼º °æÈÁõ(multiple sclerosis, MS)
1-2-10. Àå³»¹Ì»ý¹°°ú ´ç´¢º´, Á¦2Çü ´ç´¢(type 2 diabetes)
1-2-11. Àå³»¹Ì»ý¹°°ú ¿°Áõ¼º ÀåÁúȯ(inflammatory bowel disease: IBD)
1-2-12. Àå³»¹Ì»ý¹°°ú ºñ¸¸(obesity)
1-2-13. Àå³»¹Ì»ý¹°°ú °ú¹Î¼º ´ëÀåÁõÈıº(irritable bowel syndrome: IBS)
2. ±¹³»¿Ü ¿¬±¸ ÁøÇà µ¿Çâ
2-1. ±¹³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ¿¬±¸ µ¿Çâ
2-2. ±¹¿Ü ¿¬±¸ µ¿Çâ
2-2-1. ±¹Á¦ÀÎü¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ÄÁ¼Ò½Ã¾ö(International Human Microbiome Consortium, IHMC)
2-2-2. ¹Ì±¹ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ÇÁ·ÎÁ§Æ®
°¡. ÀÎü ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ÇÁ·ÎÁ§Æ®(Human Microbiome Projoect, HMP)
³ª. ±¹°¡ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È À̴ϼÅƼºê(National Microbiome Initiative, NMI)
´Ù. Áö±¸ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ÇÁ·ÎÁ§Æ®(The Earth Microbiome Project, EMP)
2-2-3. À¯·´ ÀÎü Àå³» ¸ÞŸÁö³ë¹Í½º(META genomics of the Human Intestinal Tract, MetaHIT) ÇÁ·ÎÁ§Æ®
2-2-4. ÀϺ»ÀÇ ÈÞ¸Õ ¸ÞŸ°Ô³ð ÄÁ¼Ò½Ã¿ò ÀçÆÒ(Human MetaGenome Consortium Japan, HMGJ) ÇÁ·ÎÁ§Æ®
Á¦3Àå ¾÷üµ¿Çâ ¹× ½ÃÀå Àü¸Á
1. ±¹³»¿Ü ¾÷üµ¿Çâ
1-1. ±¹³»¿Ü ¾÷üµ¿Çâ
1-1-1. Á¸½¼¾ØÁ¸½¼(Johnson & Johnson Consumer, J&J)
1-1-2. ·Î½´(Roche)
1-2. ±¹³» ¾÷üµ¿Çâ
1-2-1. °í¹ÙÀÌ¿À·¦
1-2-2. ºñÇǵµ(BIFIDO)
1-2-3. Àϵ¿Á¦¾à
1-2-4. Á¾±Ù´ç¹ÙÀÌ¿À
1-2-5. Áö³ð¾ØÄÄÆÛ´Ï
1-2-6. õ·¦
1-2-7. MDÇコÄɾî
2. ½ÃÀåÀü¸Á
2-1. ÈÞ¸Õ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå Àü¸Á ¹× ½Ã»çÁ¡
2-1-1. ÈÞ¸Õ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå Àü¸Á
2-1-2. ½Ã»çÁ¡
Âü°í¹®Çå
°ü·ÃÀ̹ÌÁö
ÀúÀÚ¼Ò°³
»ý³â¿ùÀÏ | - |
---|
ÇØ´çÀÛ°¡¿¡ ´ëÇÑ ¼Ò°³°¡ ¾ø½À´Ï´Ù.
ÁÖ°£·©Å·
´õº¸±â»óÇ°Á¤º¸Á¦°ø°í½Ã
À̺¥Æ® ±âȹÀü
Àü°øµµ¼/´ëÇб³Àç ºÐ¾ß¿¡¼ ¸¹Àº ȸ¿øÀÌ ±¸¸ÅÇÑ Ã¥
ÆǸÅÀÚÁ¤º¸
»óÈ£ |
(ÁÖ)±³º¸¹®°í |
---|---|
´ëÇ¥ÀÚ¸í |
¾Èº´Çö |
»ç¾÷ÀÚµî·Ï¹øÈ£ |
102-81-11670 |
¿¬¶ôó |
1544-1900 |
ÀüÀÚ¿ìÆíÁÖ¼Ò |
callcenter@kyobobook.co.kr |
Åë½ÅÆǸž÷½Å°í¹øÈ£ |
01-0653 |
¿µ¾÷¼ÒÀçÁö |
¼¿ïƯº°½Ã Á¾·Î±¸ Á¾·Î 1(Á¾·Î1°¡,±³º¸ºôµù) |
±³È¯/ȯºÒ
¹ÝÇ°/±³È¯ ¹æ¹ý |
¡®¸¶ÀÌÆäÀÌÁö > Ãë¼Ò/¹ÝÇ°/±³È¯/ȯºÒ¡¯ ¿¡¼ ½Åû ¶Ç´Â 1:1 ¹®ÀÇ °Ô½ÃÆÇ ¹× °í°´¼¾ÅÍ(1577-2555)¿¡¼ ½Åû °¡´É |
---|---|
¹ÝÇ°/±³È¯°¡´É ±â°£ |
º¯½É ¹ÝÇ°ÀÇ °æ¿ì Ãâ°í¿Ï·á ÈÄ 6ÀÏ(¿µ¾÷ÀÏ ±âÁØ) À̳»±îÁö¸¸ °¡´É |
¹ÝÇ°/±³È¯ ºñ¿ë |
º¯½É ȤÀº ±¸¸ÅÂø¿À·Î ÀÎÇÑ ¹ÝÇ°/±³È¯Àº ¹Ý¼Û·á °í°´ ºÎ´ã |
¹ÝÇ°/±³È¯ ºÒ°¡ »çÀ¯ |
·¼ÒºñÀÚÀÇ Ã¥ÀÓ ÀÖ´Â »çÀ¯·Î »óÇ° µîÀÌ ¼Õ½Ç ¶Ç´Â ÈÑ¼ÕµÈ °æ¿ì ·¼ÒºñÀÚÀÇ »ç¿ë, Æ÷Àå °³ºÀ¿¡ ÀÇÇØ »óÇ° µîÀÇ °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì ·º¹Á¦°¡ °¡´ÉÇÑ »óÇ° µîÀÇ Æ÷ÀåÀ» ÈѼÕÇÑ °æ¿ì ·½Ã°£ÀÇ °æ°ú¿¡ ÀÇÇØ ÀçÆǸŰ¡ °ï¶õÇÑ Á¤µµ·Î °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì ·ÀüÀÚ»ó°Å·¡ µî¿¡¼ÀÇ ¼ÒºñÀÚº¸È£¿¡ °üÇÑ ¹ý·üÀÌ Á¤ÇÏ´Â ¼ÒºñÀÚ Ã»¾àöȸ Á¦ÇÑ ³»¿ë¿¡ ÇØ´çµÇ´Â °æ¿ì |
»óÇ° Ç°Àý |
°ø±Þ»ç(ÃâÆÇ»ç) Àç°í »çÁ¤¿¡ ÀÇÇØ Ç°Àý/Áö¿¬µÉ ¼ö ÀÖÀ½ |
¼ÒºñÀÚ ÇÇÇغ¸»ó |
·»óÇ°ÀÇ ºÒ·®¿¡ ÀÇÇÑ ±³È¯, A/S, ȯºÒ, Ç°Áúº¸Áõ ¹× ÇÇÇغ¸»ó µî¿¡ °üÇÑ »çÇ×Àº¼ÒºñÀÚºÐÀïÇØ°á ±âÁØ (°øÁ¤°Å·¡À§¿øȸ °í½Ã)¿¡ ÁØÇÏ¿© ó¸®µÊ ·´ë±Ý ȯºÒ ¹× ȯºÒÁö¿¬¿¡ µû¸¥ ¹è»ó±Ý Áö±Þ Á¶°Ç, ÀýÂ÷ µîÀº ÀüÀÚ»ó°Å·¡ µî¿¡¼ÀǼҺñÀÚ º¸È£¿¡ °üÇÑ ¹ý·ü¿¡ µû¶ó ó¸®ÇÔ |
(ÁÖ)ÀÎÅÍÆÄÅ©Ä¿¸Ó½º´Â ȸ¿ø´ÔµéÀÇ ¾ÈÀü°Å·¡¸¦ À§ÇØ ±¸¸Å±Ý¾×, °áÁ¦¼ö´Ü¿¡ »ó°ü¾øÀÌ (ÁÖ)ÀÎÅÍÆÄÅ©Ä¿¸Ó½º¸¦ ÅëÇÑ ¸ðµç °Å·¡¿¡ ´ëÇÏ¿©
(ÁÖ)KGÀ̴Ͻýº°¡ Á¦°øÇÏ´Â ±¸¸Å¾ÈÀü¼ºñ½º¸¦ Àû¿ëÇÏ°í ÀÖ½À´Ï´Ù.
¹è¼Û¾È³»
±³º¸¹®°í »óÇ°Àº Åùè·Î ¹è¼ÛµÇ¸ç, Ãâ°í¿Ï·á 1~2Àϳ» »óÇ°À» ¹Þ¾Æ º¸½Ç ¼ö ÀÖ½À´Ï´Ù.
Ãâ°í°¡´É ½Ã°£ÀÌ ¼·Î ´Ù¸¥ »óÇ°À» ÇÔ²² ÁÖ¹®ÇÒ °æ¿ì Ãâ°í°¡´É ½Ã°£ÀÌ °¡Àå ±ä »óÇ°À» ±âÁØÀ¸·Î ¹è¼ÛµË´Ï´Ù.
±ººÎ´ë, ±³µµ¼Ò µî ƯÁ¤±â°üÀº ¿ìü±¹ Åù踸 ¹è¼Û°¡´ÉÇÕ´Ï´Ù.
¹è¼Ûºñ´Â ¾÷ü ¹è¼Ûºñ Á¤Ã¥¿¡ µû¸¨´Ï´Ù.